Northland Capital Partners’ Vadim Alexandre discusses the latest update from ImmuPharma PLC on their Lupuzor Phase III study in this exclusive interview with DirectorsTalk
Northland Capital Partners’ Vadim Alexandre discusses ImmuPharma PLC in this exclusive interview with DirectorsTalk
Northland Capital Partners Head of research Vadim Alexandre talks to DirectorsTalk about the phase III trial update announced by Immupharma Plc (LON:IMM). Vadim talks us through the highlights and the
ImmuPharma PLC (LSE:IMM) the specialist drug discovery and development company, has told DirectorsTalk that at its General Meeting today, held in connection with the Placing and Subscription, as announced on 5
UK Broker Upgrades / Downgrades Code Company Broker Recomm. From Recomm. To Price From Price To Upgrades ABF Associated British Foods Plc Nomura Neutral Neutral 2815 3215 DGE
© 2023 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
